Breaking News, Trials & Filings

D-Pharm Begins Ukraine Stroke Trial

Will test THR-18 in conjunction with tPA

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

D-Pharm Ltd. has received approval from regulatory authorities in the Ukraine to commence a Phase IIa clinical study of THR-18, to be given with the clot buster drug tissue plasminogen activator (tPA), in patients with acute ischemic stroke. THR-18 is a synthetic therapeutic peptide derived from plasminogen activator inhibitor-1 (PAI-1). This is a double-blind, placebo-controlled, escalating single-dose trial to assess the safety, pharmacokinetics and pharmacodynamics of THR-18 given with tPA t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters